Pharma Foods International Co., Ltd. (2929.T)
JPY 853.0
(2.4%)
JPY 853.0
(2.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 6.02 Billion JPY | 44.47% |
| 2023 | 4.15 Billion JPY | 131.81% |
| 2022 | 1.6 Billion JPY | -69.61% |
| 2021 | 5.85 Billion JPY | 527.74% |
| 2020 | 1 Billion JPY | 29.91% |
| 2019 | 767.46 Million JPY | 61.04% |
| 2018 | 407.83 Million JPY | -65.98% |
| 2017 | 205.43 Million JPY | 85.15% |
| 2016 | 76.21 Million JPY | 1046.58% |
| 2015 | -153.9 Million JPY | -145.91% |
| 2014 | 37.36 Million JPY | -69.32% |
| 2013 | 319.48 Million JPY | 128.81% |
| 2012 | 91.9 Million JPY | 58.17% |
| 2011 | -9.37 Million JPY | 10.59% |
| 2010 | 60.47 Million JPY | 309.44% |
| 2009 | -155 Million JPY | 70.97% |
| 2008 | -380 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 644 Million JPY | -64.01% |
| 2024 Q4 | 1.83 Billion JPY | 19.28% |
| 2024 Q2 | 1.1 Billion JPY | 45.28% |
| 2024 Q3 | 1.88 Billion JPY | 70.55% |
| 2023 FY | - JPY | 131.81% |
| 2023 Q2 | 1.29 Billion JPY | 160.23% |
| 2023 Q4 | 2.04 Billion JPY | -19.2% |
| 2023 Q1 | -2.14 Billion JPY | -1102.34% |
| 2023 Q3 | 2.52 Billion JPY | 95.51% |
| 2022 Q4 | 214 Million JPY | 121.19% |
| 2022 FY | - JPY | -69.61% |
| 2022 Q3 | -1.01 Billion JPY | -298.43% |
| 2022 Q2 | 509 Million JPY | -68.75% |
| 2022 Q1 | 1.62 Billion JPY | -46.82% |
| 2021 Q2 | 1.37 Billion JPY | 198.43% |
| 2021 FY | - JPY | 527.74% |
| 2021 Q4 | 3.06 Billion JPY | 10.19% |
| 2021 Q3 | 2.77 Billion JPY | 102.75% |
| 2021 Q1 | -1.39 Billion JPY | -235.76% |
| 2020 FY | - JPY | 29.91% |
| 2020 Q4 | 1.02 Billion JPY | -24.84% |
| 2020 Q3 | 1.36 Billion JPY | 270.68% |
| 2020 Q1 | -756.35 Million JPY | -206.31% |
| 2020 Q2 | -799.76 Million JPY | -5.74% |
| 2019 Q2 | 156.55 Million JPY | 144.54% |
| 2019 FY | - JPY | 61.04% |
| 2019 Q4 | 711.46 Million JPY | 269.83% |
| 2019 Q1 | -351.47 Million JPY | -162.18% |
| 2019 Q3 | 192.37 Million JPY | 22.88% |
| 2018 Q4 | 565.21 Million JPY | 510.99% |
| 2018 Q2 | 36.64 Million JPY | 159.05% |
| 2018 Q1 | -62.05 Million JPY | -109.8% |
| 2018 FY | - JPY | -65.98% |
| 2018 Q3 | -137.52 Million JPY | -475.29% |
| 2017 Q3 | 685.11 Million JPY | 641.69% |
| 2017 FY | - JPY | 85.15% |
| 2017 Q4 | 633.27 Million JPY | -7.57% |
| 2017 Q2 | 92.37 Million JPY | 169.25% |
| 2017 Q1 | -133.39 Million JPY | -123.68% |
| 2016 FY | - JPY | 1046.58% |
| 2016 Q2 | 150.59 Million JPY | 153.71% |
| 2016 Q1 | -280.35 Million JPY | -467.42% |
| 2016 Q3 | 246.89 Million JPY | 63.95% |
| 2016 Q4 | 563.3 Million JPY | 128.15% |
| 2015 Q3 | -153.24 Million JPY | -269.97% |
| 2015 Q2 | 90.15 Million JPY | 184.14% |
| 2015 Q1 | -107.15 Million JPY | -167.49% |
| 2015 FY | - JPY | -145.91% |
| 2015 Q4 | 76.3 Million JPY | 149.79% |
| 2014 Q4 | 158.75 Million JPY | 271.21% |
| 2014 Q1 | 76.94 Million JPY | -69.24% |
| 2014 FY | - JPY | -69.32% |
| 2014 Q2 | 9.29 Million JPY | -87.92% |
| 2014 Q3 | -92.72 Million JPY | -1097.4% |
| 2013 FY | - JPY | 128.81% |
| 2013 Q1 | 116.03 Million JPY | -34.08% |
| 2013 Q2 | 78.56 Million JPY | -32.3% |
| 2013 Q3 | 82.58 Million JPY | 5.12% |
| 2013 Q4 | 250.11 Million JPY | 202.87% |
| 2012 Q4 | 176.03 Million JPY | 343.8% |
| 2012 FY | - JPY | 58.17% |
| 2012 Q2 | -8.31 Million JPY | -162.25% |
| 2012 Q3 | 39.66 Million JPY | 576.9% |
| 2012 Q1 | 13.36 Million JPY | -81.64% |
| 2011 Q2 | 27.9 Million JPY | 229.22% |
| 2011 FY | - JPY | 10.59% |
| 2011 Q4 | 72.76 Million JPY | 6.71% |
| 2011 Q3 | 68.19 Million JPY | 144.39% |
| 2011 Q1 | -21.59 Million JPY | -153.53% |
| 2010 Q2 | 53.48 Million JPY | 405.88% |
| 2010 FY | - JPY | 309.44% |
| 2010 Q1 | -17.48 Million JPY | 85.83% |
| 2010 Q4 | 40.34 Million JPY | -19.29% |
| 2010 Q3 | 49.98 Million JPY | -6.54% |
| 2009 Q4 | -123.39 Million JPY | -14349.31% |
| 2009 Q3 | 866 Thousand JPY | 124.55% |
| 2009 Q1 | -700 Thousand JPY | 0.0% |
| 2009 FY | - JPY | 70.97% |
| 2009 Q2 | -3.52 Million JPY | -404.0% |
| 2008 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.312% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 102.142% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 96.775% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -954.518% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 83.409% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 50.917% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 94.16% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -365.661% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 67.17% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 32.899% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -64.06% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -329.152% |
| Tsumura & Co. | 30.77 Billion JPY | 80.434% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 67.837% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -14.229% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 83.057% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 12.511% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 65.637% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 41.521% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 260.56% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 20.283% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 943.277% |
| MedRx Co., Ltd | -884.51 Million JPY | 780.711% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -8.755% |
| Solasia Pharma K.K. | -635 Million JPY | 1048.189% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 353.631% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 34.29% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 83.671% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 1218.544% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 76.703% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -18.021% |